NewsRoom Articles - BioMedWire (BMW)

ThursdayDec 11, 2025 10:00 am

Health Experts Suggest How Public Trust Can Be Restored in US Healthcare

After the pandemic, public trust in the U.S. healthcare system plummeted, and officials at the local level took the hardest hit when compared to federal health officials. As things stand, even state and federal health officials are losing even the little trust that the public still had in them. For a healthcare system to function, public trust is vital because people want to believe that the professionals they entrust with their health have their best interests at heart. It is therefore alarming that public trust in healthcare professionals is at an all-time low, and fixing the healthcare crisis needs to…

TuesdayDec 09, 2025 10:00 am

US to End Mandatory Vaccination of Newborns Against Hepatitis B

Since 1991, there has existed a recommendation requiring all newborns to receive a vaccine against Hepatitis B at birth. However, an advisory panel on vaccines voted on Friday to end this recommendation and instead recommended that only babies whose mothers have had a positive test for hepatitis B should receive the shot at birth. The panel in question, ACIP (Advisory Committee on Immunization Practices), advises the CDC on vaccination policy in the U.S. During their recent meeting, the panel voted 8-3 in favor of letting individuals decide whether to have their newborns receive the vaccine or not. This only applies…

MondayDec 08, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Receives Strong Vote of Confidence from Zacks Report Despite Muted Market Response to Clinical Milestone

The report maintains $25 per share valuation for Soligenix, based on a probability-adjusted discounted cash flow model that considers potential future revenues. The centerpiece of the Zacks analysis focuses on what is characterized as a “very encouraging” 48% blinded response rate. With 50 patients now enrolled out of a planned 80-patient study, the company remains on track for the interim analysis to occur in the second quarter of 2026. When a late-stage clinical trial reports response rates nearly double what researchers expected, yet the stock market barely reacts, seasoned analysts take notice and wonder if investors are missing something significant.…

FridayDec 05, 2025 10:00 am

Nasal Drops Hold Promise in Fighting Deadly Brain Cancer

The fight against glioblastoma, a deadly brain cancer, has been boosted by new research conducted at Washington University that has developed nasal drops which can travel through nerves found in the nose and reach different parts of our central nervous system in order to fight the glioblastoma cells there. Preliminary results revealed that this novel medication safely reached the intended target and protected the mice against the fatal tumors. Alexander Stegh, a neurosurgeon at the university, explains that their approach offers hope for more effective and safer treatments for this deadliest brain cancer and possibly other cancers that are resistant…

ThursdayDec 04, 2025 10:00 am

Cancer Immunotherapy Could Be Boosted by Targeting Pathways of DNA Repair

A newly published study shows that the fight against cancer could be boosted by considering approaches that seek to disrupt the mechanisms through which tumor cells respond to damage to their DNA. Targeting these pathways could make immunotherapy more effective for a lot more people. The study team led by Tang Z. focused on DDR (DNA Damage Response), a process at the cellular level in which cells undertake a variety of measures to fix any damage to their DNA. This repair process is intended to keep the tumor functioning and able to continue growing and spreading. By disrupting DDR, cancer…

ThursdayDec 04, 2025 9:00 am

Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations

BioMedWire Editorial Coverage: Chronic illnesses and rare disorders among older Americans represent a rapidly intensifying challenge for the U.S. healthcare system, with the National Institutes of Health estimating that more than 30 million people nationwide are living with a rare disease. Most of these conditions have no FDA-approved therapies, leaving older adults particularly at risk as age-related changes can mask or delay accurate diagnosis. This growing strain on care has heightened the need for novel treatments that address significant unmet medical needs. Soligenix Inc. (NASDAQ: SNGX) (profile), a late-stage biopharmaceutical developer, is advancing several rare-disease therapies, including HyBryte[TM] (synthetic hypericin)…

TuesdayDec 02, 2025 10:00 am

Could Copying Lessons from Europe Help America Fix its Healthcare System?

The steep cost of healthcare in the U.S. has always been, and is becoming an even bigger political issue with each passing year. The issue was at the center of the recent shutdown of the federal government and the shutdown was only ended after a promise that the expiring healthcare subsidies would be voted on this month. Health insurance costs are soaring while citizens grapple with a high cost of living. According to a report published by the OECD last month, the per capita expenditure on healthcare in the U.S. far exceeds the per capita cost in other countries. Despite…

TuesdayDec 02, 2025 9:00 am

Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now

BioMedWire Editorial Coverage: Chronic conditions and rare diseases in the aging population present an urgent and expanding challenge within the U.S. healthcare system, especially as more than 30 million Americans are affected by rare diseases, according to the National Institutes of Health. The vast majority of these conditions lack any FDA-approved treatment, leaving older adults especially vulnerable as age-related symptoms often obscure or delay diagnosis. This rising burden has increased demand for new therapies that can address real unmet need. Soligenix Inc. (NASDAQ: SNGX) (Profile), a late-stage biopharmaceutical company, is developing multiple treatments for rare diseases, including HyBryte[TM] (synthetic hypericin)…

MondayDec 01, 2025 1:15 pm

Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon the previous statistically significant Phase 3 FLASH study. The promising early results are further corroborated by an ongoing investigator-initiated study being conducted at the University of Pennsylvania. Soligenix is positioning itself to potentially deliver the first FDA-approved photodynamic therapy specifically indicated for CTCL. In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed the planned…

MondayDec 01, 2025 10:00 am

Study Uncovers Surprising Connection Between Choline, Obesity and Brain Inflammation

For a long time, the scientific community has known that anything that causes harm to the body usually also harms our brains. Conditions like insulin resistance, obesity and high blood pressure strain the body’s metabolic and vascular systems. With time, this stress accelerates cognitive decline and amplifies Alzheimer’s risk. Now, a new study conducted by a team at Arizona State University (ASU) together with collaborators elsewhere has shown that the harmful effects often start much earlier than had initially been thought. They observed that obese young adults exhibited a pattern of subtle changes suggesting early brain damage. These same patterns…